will provide World Health Organization
(WHO) with access to pandemic influenza
vaccine manufacturing technology in developing countries. WHO may also give sublicenses to firms in various developing countries.
The agreement, which was signed by Nobilon, the company’s human vaccine business unit, grants the organization a nonexclusive license to develop, register, manufacture, use, and sell seasonal and pandemic live, attenuated, influenza vaccines (LAIV), produced on embryonated chicken eggs.
WHO will be permitted to grant a sublicense to vaccine manufacturers in developing countries working within the framework of the WHO Global Vaccine Action Plan. Sublicensees will be able to provide vaccines to the public sector of developing countries royalty-free.
Egg-based LAIV technology is specifically considered attractive for this purpose, because the manufacturing technology process is easier to transfer, capital investment is lower, and yields are higher as compared to inactivated influenza vaccines, according to Schering-Plough.
To comment on this story, go to BLOGbiotech.